Cantor Fitzgerald Reiterates Overweight Rating on MannKind (MNKD)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/26/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Nasdaq lags on angst over AI spending ahead of earnings reports
MannKind Corporation Reports 2019 Third Quarter Preliminary Financial Results
November 6, 2019 8:01 AM EST3Q 2019 Total Revenues of $14.6 million; +227% vs. 3Q 2018° 3Q 2019 Afrezza Net Revenue was $6.4 million; +46% vs. 3Q 2018    Afrezza sold to our marketing partner in Brazil for launch was $0.7 million°  3Q 2019 Collaborations and Services Revenue was $8.2 million Debt financing completed providing up to $75.0 million in non-dilutive capital Received second $12.5 million milestone payment from United Therapeutics in November 2019Advanced Technosphere® formulations of sumatriptan and tadalafil into nonclinical pharmacology studies... More
